Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Antioxidant properties of the triaminopyridine, flupirtine.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Interferon in relapsing-remitting multiple sclerosis.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Extension CombiRx data show no benefit of combined MS drugs
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Chemotherapeutics in the treatment of multiple sclerosis.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Intas launches biosimilar version of Rituximab
Repurposing drugs for disease modification in multiple sclerosis
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Pages